WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). The interim results show that four weekly ...

First Patient Dosed in Phase 1b Study of Age-Related Hearing Loss; Additional Phase 1b Study for Severe SNHL Patients to Start This Quarter WOBURN, Mass.--(BUSINESS WIRE)-- Frequency Therapeutics, Inc ...

A peer‑reviewed study finds that during prolonged high‑frequency firing, parvalbumin‑expressing interneurons lose action potential strength along their axons, even when somatic firing remains stable.

LINCOLN, Neb. (UNL Press Release) - Vehicles in ditches and medians. Nights without power and heat. Injuries suffered. Lives lost. For those in the Heartland, where the frying pan of summer gives way ...

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused ...